| dc.contributor.author | Newton, G | |
| dc.contributor.author | Stewart, M | |
| dc.contributor.other | Jenkins, K | |
| dc.contributor.other | Perrior, T | |
| dc.contributor.other | Negoita-Giras, G | |
| dc.contributor.other | Crosby, S | |
| dc.contributor.other | Hopkins, A | |
| dc.coverage.spatial | International | |
| dc.date.accessioned | 2020-08-19T09:51:02Z | |
| dc.date.issued | 2014-08-28 | |
| dc.identifier | GB2014050521W | |
| dc.identifier | WO2014128486 (and associated family) | |
| dc.identifier.citation | 2014 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3986 | |
| dc.description.abstract | Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases &Igr;&Kgr;&Kgr;&egr; and/or TBK-1 in which one of V and W is N, and the other of V and W is C-H; and R1, R2, R3 and R4 are as defined in the specification. The invention also provides uses of the compounds and compositions containing them. | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.subject | Kinase | |
| dc.subject | Inflammation | |
| dc.subject | Cancer | |
| dc.title | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | |
| dc.type | Patent | |
| rioxxterms.licenseref.startdate | 2014-08-28 | |
| rioxxterms.type | Other | |
| pubs.filed-date | 2014-02-21 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.patent-status | Granted in multiple territories | |
| pubs.start-date | 2016-08-03 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicinal Chemistry 3 | |
| dc.contributor.icrauthor | Newton, Gary | |
